NCT03589066View on ClinicalTrials.gov

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Parkinson Disease
Interventions
DRUG

LY03003

28 mg intramuscular suspension

Trial Locations (2)

30331

Atlanta Center for Medical Research, Atlanta

33009

MD Clinical, Hallandale

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT03589066 - Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter